Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alexia, Buzzonetti"'
Autor:
Giuseppina Raspaglio, Marianna Buttarelli, Flavia Filippetti, Alessandra Battaglia, Alexia Buzzonetti, Giovanni Scambia, Daniela Gallo
Publikováno v:
Cell Death and Disease, Vol 12, Iss 10, Pp 1-13 (2021)
Abstract Cervical cancer (CC) is the fourth most common cause of cancer-related death in women. According to international guidelines, a standard treatment for locally advanced cervical cancer (LACC) consists of exclusive concurrent chemoradiation tr
Externí odkaz:
https://doaj.org/article/41e997f424444c508b4e64c93597c203
Autor:
Giovanni Scambia, Marco Fossati, Giuseppe Angelico, Veronica Iannucci, Nicole Zampetti, Valentina Iacobelli, Anna Fagotti, Andrea Fattorossi, Tina Pasciuto, Alessia Piermattei, Alessandra Battaglia, Camilla Nero, Alexia Buzzonetti
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5200, p 5200 (2021)
Volume 13
Issue 20
Cancers, Vol 13, Iss 5200, p 5200 (2021)
Volume 13
Issue 20
Simple Summary PD-1/PD-L1 axis blockade immunotherapy leverages on assessment of tumour PD-L1 status by immunohistochemistry for identifying cancer patients’ who would benefit most from this therapy. Because some PD-L1 negative cancer patients also
Autor:
Alexia Buzzonetti, Gabriele Babini, Giovanni Scambia, Alessandra Battaglia, Luca Massimi, Antonio Ruggiero, Alessia Granitto, Maurizio Martini, Gianpiero Tamburrini, Daniela Meco, Tiziana Servidei, Riccardo Riccardi
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 4
International Journal of Molecular Sciences, Vol 22, Iss 1877, p 1877 (2021)
Volume 22
Issue 4
International Journal of Molecular Sciences, Vol 22, Iss 1877, p 1877 (2021)
Childhood ependymomas are heterogenous chemoresistant neoplasms arising from aberrant stem-like cells. Epigenome deregulation plays a pivotal role in ependymoma pathogenesis, suggesting that epigenetic modifiers hold therapeutic promise against this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::162b5c3676a527296851283496c67529
https://hdl.handle.net/10807/223485
https://hdl.handle.net/10807/223485
Autor:
Alexia Buzzonetti, Alessandra Battaglia, Yolanda D. Mahnke, Giovanni Scambia, Madi Madiyalakan, Andrea Fattorossi, Christopher F. Nicodemus, Marco Fossati
Publikováno v:
Cancer immunology, immunotherapy : CII. 69(7)
The original version of this article unfortunately contained a mistake.
Autor:
Alessandra Battaglia, Yolanda D. Mahnke, Giovanni Scambia, Christopher F. Nicodemus, Madi Madiyalakan, Alexia Buzzonetti, Andrea Fattorossi, Marco Fossati
The standard-of-care (SOC) first-line therapy for ovarian cancer (OC) patients is plagued with high relapse rates. Several studies indicated the immune system’s prominent role changing the disease course in OC patients. Chemo-immunotherapy regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0249c4546fb40dd95a6168b6e7737e0f
http://hdl.handle.net/10807/167347
http://hdl.handle.net/10807/167347
Introduction Despite encouraging phase I and II study results, vaccination of ovarian cancer patients with abagovomab – an anti-idiotypic mAb that mimics the ovarian cancer CA125 protein – failed to demonstrate efficacy in the phase III trial nam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e9e433bda7ed7317423f9be1e8fd34
http://hdl.handle.net/10807/111940
http://hdl.handle.net/10807/111940
Autor:
Alessandra Battaglia, Giovanni Scambia, Alexia Buzzonetti, Andrea Fattorossi, Marco Fossati, Valentina Catzola
Publikováno v:
Cancer Immunology, Immunotherapy. 63:1037-1045
To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovom
Autor:
Giovanni Scambia, Alessandra Battaglia, Mara Fanelli, Alexia Buzzonetti, Cinzia Baranello, Andrea Fattorossi, Marco Fossati, Valentina Catzola
Publikováno v:
Immunology. 139:109-120
Interleukin-2 (IL-2) is a mainstay for current immunotherapeutic protocols but its usefulness in patients is reduced by severe toxicities and because IL-2 facilitates regulatory T (Treg) cell development. IL-21 is a type I cytokine acting as a potent
Autor:
Giovanni Scambia, Alexia Buzzonetti, Mara Fanelli, Andrea Fattorossi, Alessandra Battaglia, Marco Petrillo, Enrica Martinelli, Gabriella Ferrandina
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 76:1546-1553
Purpose To assess how neoadjuvant chemoradiation regimens modulate the immune system state in tumor-draining lymph nodes (TDLN), in the setting of advanced cervical cancer. Methods and Materials Tumor-draining lymph nodes of patients undergoing chemo
Autor:
Giovanni Scambia, Gabriella Ferrandina, Enrica Martinelli, Cinzia Baranello, Francesco Fanfani, Andrea Fattorossi, Alexia Buzzonetti, Alessandra Battaglia
Publikováno v:
Cancer Immunology, Immunotherapy. 58:1363-1373
We compared the immune system state in metastatic tumour draining lymph nodes (mTDLN) and metastasis free TDLN (mfTDLN) in 53 early stage cervical cancer patients to assess whether the presence of metastatic tumour cells worsen the balance between an